Mr. Speaker, I think the hon. member knows that because there is a court case involved I cannot report on the specifics. What I can say is that ACOA recognizes the comparatively high risk and the potential high gain from sectors such as biotechnology.
ACOA will continue to fill the critical financing gap that is caused by the high prospect technology base start-ups which traditional financial institutions are sometimes reluctant to do. We are not ashamed of that.